To the full analysis
Buyback calculator for Globus Medical
Globus Medical stock: key metrics
GMEDGlobus Medical had an operating margin of 16.3% and a return on invested capital (ROIC) of 10.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2009 | 83.6% | 32.2% | 19.2% |
| 2010 | 81.3% | 30.4% | 18.9% |
| 2011 | 79.2% | 29.4% | 18.3% |
| 2012 | 80.5% | 29.7% | 19.1% |
| 2013 | 76.9% | 23.4% | 15.8% |
| 2014 | 76.6% | 29.2% | 19.5% |
| 2015 | 75.7% | 31.6% | 20.7% |
| 2016 | 76.1% | 27.3% | 18.5% |
| 2017 | 76.3% | 25.4% | 16.9% |
| 2018 | 77.6% | 23.7% | 21.9% |
| 2019 | 77.1% | 21.9% | 19.8% |
| 2020 | 72.4% | 14.1% | 13.0% |
| 2021 | 75.0% | 17.9% | 15.6% |
| 2022 | 74.2% | 22.3% | 18.6% |
| 2023 | 65.1% | 8.5% | 7.8% |
| 2024 | 58.9% | 6.6% | 4.1% |
| 2025 | 67.4% | 16.3% | 18.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2009 | 0.0% | no data | 0.0% |
| 2010 | 23.9% | 44.7% | 20.4% |
| 2011 | 21.5% | 46.7% | 18.5% |
| 2012 | 19.1% | 47.1% | 16.5% |
| 2013 | 14.5% | 33.6% | 12.1% |
| 2014 | 15.8% | 31.3% | 13.1% |
| 2015 | 15.8% | 28.4% | 13.5% |
| 2016 | 12.5% | 21.0% | 11.2% |
| 2017 | 11.1% | 18.0% | 10.0% |
| 2018 | 13.2% | 19.5% | 12.0% |
| 2019 | 11.1% | 14.5% | 10.1% |
| 2020 | 6.8% | 8.3% | 6.1% |
| 2021 | 8.6% | 12.0% | 7.6% |
| 2022 | 10.3% | 13.2% | 9.2% |
| 2023 | 3.1% | 3.7% | 2.4% |
| 2024 | 2.5% | 3.6% | 2.0% |
| 2025 | 11.8% | 10.6% | 10.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.